Cilansetron

DB04885

small molecule investigational

Deskripsi

Cilansetron is a 5HT-3 antagonist made by Solvay Pharmaceuticals that is currently under trial phase in the EU and US.

Struktur Molekul 2D

Berat 319.4002
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The elimination half-life after 4- and 8-mg oral doses administered 3 times daily for 6 days was reported to be 1.6 to 1.9 hours.
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Rapidly absorbed orally with a bioavailability of greater than 80% in rats.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

677 Data
Buprenorphine Cilansetron may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cilansetron.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Cilansetron.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Cilansetron.
Hydrocodone Cilansetron may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Cilansetron.
Magnesium sulfate The therapeutic efficacy of Cilansetron can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Cilansetron may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Cilansetron may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Cilansetron.
Mirtazapine Cilansetron may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Cilansetron.
Orphenadrine Cilansetron may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Cilansetron may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Cilansetron.
Pramipexole Cilansetron may increase the sedative activities of Pramipexole.
Ropinirole Cilansetron may increase the sedative activities of Ropinirole.
Rotigotine Cilansetron may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Cilansetron.
Sodium oxybate Cilansetron may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Cilansetron may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Cilansetron.
Thalidomide Cilansetron may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Cilansetron may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Cilansetron.
Dicoumarol The risk or severity of adverse effects can be increased when Cilansetron is combined with Dicoumarol.
Phenindione The risk or severity of adverse effects can be increased when Cilansetron is combined with Phenindione.
Warfarin The risk or severity of adverse effects can be increased when Cilansetron is combined with Warfarin.
Phenprocoumon The risk or severity of adverse effects can be increased when Cilansetron is combined with Phenprocoumon.
Acenocoumarol The risk or severity of adverse effects can be increased when Cilansetron is combined with Acenocoumarol.
4-hydroxycoumarin The risk or severity of adverse effects can be increased when Cilansetron is combined with 4-hydroxycoumarin.
Coumarin The risk or severity of adverse effects can be increased when Cilansetron is combined with Coumarin.
(R)-warfarin The risk or severity of adverse effects can be increased when Cilansetron is combined with (R)-warfarin.
Ethyl biscoumacetate The risk or severity of adverse effects can be increased when Cilansetron is combined with Ethyl biscoumacetate.
Fluindione The risk or severity of adverse effects can be increased when Cilansetron is combined with Fluindione.
Clorindione The risk or severity of adverse effects can be increased when Cilansetron is combined with Clorindione.
Diphenadione The risk or severity of adverse effects can be increased when Cilansetron is combined with Diphenadione.
Tioclomarol The risk or severity of adverse effects can be increased when Cilansetron is combined with Tioclomarol.
(S)-Warfarin The risk or severity of adverse effects can be increased when Cilansetron is combined with (S)-Warfarin.
Ethanol Cilansetron may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Cilansetron may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Cilansetron.
Fluvoxamine The risk or severity of adverse effects can be increased when Cilansetron is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Cilansetron is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Cilansetron is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Cilansetron is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Cilansetron is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Cilansetron is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Cilansetron is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Cilansetron is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Cilansetron is combined with Escitalopram.
Zimelidine The risk or severity of adverse effects can be increased when Cilansetron is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Cilansetron is combined with Dapoxetine.
Milnacipran The risk or severity of adverse effects can be increased when Cilansetron is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Cilansetron is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Cilansetron is combined with Seproxetine.
Indalpine The risk or severity of adverse effects can be increased when Cilansetron is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Cilansetron is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Cilansetron is combined with Alaproclate.
Zopiclone The risk or severity of adverse effects can be increased when Cilansetron is combined with Zopiclone.
Botulinum toxin type B The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Cilansetron.
Botulinum toxin type A The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Cilansetron.
Tryptophan The risk or severity of CNS depression can be increased when Tryptophan is combined with Cilansetron.
Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Cilansetron.
Lorazepam The risk or severity of CNS depression can be increased when Lorazepam is combined with Cilansetron.
Ethchlorvynol The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Cilansetron.
Succinylcholine The risk or severity of CNS depression can be increased when Succinylcholine is combined with Cilansetron.
Reserpine The risk or severity of CNS depression can be increased when Reserpine is combined with Cilansetron.
Eletriptan The risk or severity of CNS depression can be increased when Eletriptan is combined with Cilansetron.
Enflurane The risk or severity of CNS depression can be increased when Enflurane is combined with Cilansetron.
Temazepam The risk or severity of CNS depression can be increased when Temazepam is combined with Cilansetron.
Reboxetine The risk or severity of CNS depression can be increased when Reboxetine is combined with Cilansetron.
Butabarbital The risk or severity of CNS depression can be increased when Butabarbital is combined with Cilansetron.
Butalbital The risk or severity of CNS depression can be increased when Butalbital is combined with Cilansetron.
Methysergide The risk or severity of CNS depression can be increased when Methysergide is combined with Cilansetron.
Cabergoline The risk or severity of CNS depression can be increased when Cabergoline is combined with Cilansetron.
Phenytoin The risk or severity of CNS depression can be increased when Phenytoin is combined with Cilansetron.
Topiramate The risk or severity of CNS depression can be increased when Topiramate is combined with Cilansetron.
Clemastine The risk or severity of CNS depression can be increased when Clemastine is combined with Cilansetron.
Venlafaxine The risk or severity of CNS depression can be increased when Venlafaxine is combined with Cilansetron.
Etomidate The risk or severity of CNS depression can be increased when Etomidate is combined with Cilansetron.
Morphine The risk or severity of CNS depression can be increased when Morphine is combined with Cilansetron.
Talbutal The risk or severity of CNS depression can be increased when Talbutal is combined with Cilansetron.
Pentobarbital The risk or severity of CNS depression can be increased when Pentobarbital is combined with Cilansetron.
Valproic acid The risk or severity of CNS depression can be increased when Valproic acid is combined with Cilansetron.
Zolmitriptan The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Cilansetron.
Codeine The risk or severity of CNS depression can be increased when Codeine is combined with Cilansetron.
Dihydroergotamine The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Cilansetron.
Amitriptyline The risk or severity of CNS depression can be increased when Amitriptyline is combined with Cilansetron.
Tolcapone The risk or severity of CNS depression can be increased when Tolcapone is combined with Cilansetron.
Hydromorphone The risk or severity of CNS depression can be increased when Hydromorphone is combined with Cilansetron.
Olanzapine The risk or severity of CNS depression can be increased when Olanzapine is combined with Cilansetron.
Cetirizine The risk or severity of CNS depression can be increased when Cetirizine is combined with Cilansetron.
Protriptyline The risk or severity of CNS depression can be increased when Protriptyline is combined with Cilansetron.
Trimethadione The risk or severity of CNS depression can be increased when Trimethadione is combined with Cilansetron.
Clobazam The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Cilansetron.
Chlorzoxazone The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Cilansetron.
Clozapine The risk or severity of CNS depression can be increased when Clozapine is combined with Cilansetron.
Meprobamate The risk or severity of CNS depression can be increased when Meprobamate is combined with Cilansetron.
Thiethylperazine The risk or severity of CNS depression can be increased when Thiethylperazine is combined with Cilansetron.

Target Protein

5-hydroxytryptamine receptor 3A HTR3A

Referensi & Sumber

Artikel (PubMed)
  • PMID: 15757394
    Chey WD, Cash BD: Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea. Expert Opin Investig Drugs. 2005 Feb;14(2):185-93.
  • PMID: 15869320
    Authors unspecified: Cilansetron: KC 9946. Drugs R D. 2005;6(3):169-73.
  • PMID: 16842448
    Tack J, Fried M, Houghton LA, Spicak J, Fisher G: Systematic review: the efficacy of treatments for irritable bowel syndrome--a European perspective. Aliment Pharmacol Ther. 2006 Jul 15;24(2):183-205.

Contoh Produk & Brand

Produk: 0 • International brands: 1
International Brands
  • Calmactin

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul